[
  {
    "table_index": 1,
    "headers": [],
    "rows": [
      [
        "End Note"
      ],
      [
        "Procite"
      ],
      [
        "Reference Manager"
      ]
    ],
    "row_count": 3,
    "column_count": 1
  },
  {
    "table_index": 2,
    "headers": [
      "Arranged by year",
      "Response criteria"
    ],
    "rows": [
      [
        "Rochester I78",
        "ALP 2× ULN"
      ],
      [
        "Barcelona60",
        "Reduction in ALP 40% from baseline or normalization of ALP"
      ],
      [
        "Paris I149",
        "ALP 3× ULN; AST 2× ULN; and TB 1 mg/dL"
      ],
      [
        "Rotterdam150",
        "TB <1× ULN and albumin >1× LLN"
      ],
      [
        "Toronto151",
        "ALP 1.67× ULN"
      ],
      [
        "Paris II152",
        "ALP 1.5× ULN; AST 1.5× ULN; and TB 1 mg/dL"
      ],
      [
        "Rochester II79",
        "ALP 2× ULN"
      ],
      [
        "Global77",
        "ALP 2× ULN"
      ]
    ],
    "row_count": 8,
    "column_count": 2
  },
  {
    "table_index": 3,
    "headers": [
      "Liver tests every 3‐6 months"
    ],
    "rows": [
      [
        "TSH annually"
      ],
      [
        "Bone mineral densitometry every 2 years"
      ],
      [
        "Vitamins A, D, E and prothrombin time annually if bilirubin >2.0"
      ],
      [
        "Upper endoscopy every 1‐3 years if cirrhotic, Mayo risk score >4.1, or transient elastography shows a score ≥17 kPa*"
      ],
      [
        "Ultrasound with or without alpha fetoprotein in patients with known or suspected cirrhosis†and men every 6 months"
      ]
    ],
    "row_count": 5,
    "column_count": 1
  }
]